Pharmacodynamics of 5-Fluorouracil and Leucovorin
Fluoropyrimidine therapy is a corner-stone of chemotherapeutic management of metastatic cancer. Although only about 15% of patients respond to initial single-agent FUra therapy, a greater number may have disease stabilization with comparatively mild toxicity1,2. Fifteen years ago, we reported that continuous intraportal infusion of Fyra in a significant prolonged survival compared to historical controls3. Since then, significant discoveries of the mechanisms of action of FUra and attempts at rational approaches in its application have been made.
KeywordsFolinic Acid Group FUra Murine Colon Adenocarcinoma Fluoropyrimidine Therapy Chemotherapeutic Management
Unable to display preview. Download preview PDF.
- 1.B. Gustaysson and L. O. Hafström, Adjuvant and palliative treatment of colo-rectal cancer with fluorinated pyrimidines - a pharmacological and clinical review, Acta Chir Scand Suppl 504 (1981).Google Scholar
- 3.O. Almersjö, L. O. Hafström, and B. Gustaysson, Results of regional portal infusion of 5-fluorouracil to patients with primary and secondary liver cancer, Acta Chir Gyn Fenn 65: 27 (1976).Google Scholar
- 5.C. P. Spears, B. G. Gustaysson, and R. Frösing, Folinic acid modulation of fluorouracil: kinetics of bolus administration, Invest New Drugs 6: in press (1988).Google Scholar
- 7.C. P. Spears and B. G. Gustaysson, Methods for thymidylate synthase pharmacodynamies: serial biopsy, free and total TS, FdUMP and dUMP, and H4PteGlu and CH -H PteGlu assays, in: “The Expanding Role of Folates and Fluoropyrimidines in Cancer Chemotherapy”, Y. Rustum and J. McGuire eds., Plenum Publ Corp, N.Y. (1988).Google Scholar